• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bausch + Lomb Launches Zenlens® CHROMA HOA™ in the United States

    5/14/25 6:59:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care
    Get the next $BLCO alert in real time by email

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Zenlens CHROMA HOA scleral contact lenses. Designed to correct advanced higher-order aberrations (HOA), this custom, wavefront-guided scleral lens technology delivers enhanced vision and improves clarity by reducing symptoms such as halos and glare.

    "Zenlens CHROMA HOA is a high-quality, customizable lens that fills a critical gap in scleral lens vision correction, especially for patients with complex corneal irregularities," said Yang Yang, president, Global Vision Care, Bausch + Lomb. "Eye care professionals in the U.S. now have a new solution for patients that previously had limited options to improve vision quality."

    HOA correction starts with a secure lens fit1, which can be achieved through proprietary Zenlens technologies, including SmartCurve™ and Bi-Elevation™. Once lens stability is secured, custom HOA correction is applied to the lens to effectively reduce higher-order aberrations and enhance vision by minimizing blurring and distortion.

    "For years, I've had patients who struggle with visual distortions caused by higher-order aberrations, and there was little I could do beyond basic correction," said Jason Jedlicka, OD, chief of cornea and contact lens service and clinical professor, Indiana University School of Optometry. "With Zenlens CHROMA HOA, I can offer a level of precision that wasn't previously possible, and my patients can experience sharper vision and improved clarity, which has a significant impact on their quality of life."

    Bausch + Lomb is collaborating with Advance Medical and OVITZ® to help eye care professionals integrate Zenlens CHROMA HOA into their practices. Advance Medical's FocalPoints® software platform – a leading platform for specialty lens manufacturing – enables seamless and precise production of the Zenlens CHROMA HOA design. OVITZ, the first company to develop an aberrometry system specifically for HOA correction, is providing its latest device, the xwave aberrometer.

    For more information on Zenlens CHROMA HOA, visit www.bauschsvp.com/lenses/zenlens.

    Important Safety Information for Gas Permeable and Customized Soft Contact Lenses

    WARNINGS:

    Patients should be advised of the following warnings pertaining to contact lens wear:

    • Problems with contact lenses and lens care products could result in serious injury to the eye. It is essential that patients follow their eyecare practitioner's directions and all labeling instructions for proper use of lenses and lens care products, including the lens case. Eye problems, including corneal ulcers, can develop rapidly and lead to loss of vision.
    • Daily wear lenses are not indicated for overnight wear, and patients should be instructed not to wear lenses while sleeping. Clinical studies have shown that the risk of serious adverse reactions is increased when daily wear lenses are worn overnight.
    • Studies have shown that contact lens wearers who are smokers have a higher incidence of adverse reactions than nonsmokers.
    • If a patient experiences eye discomfort, excessive tearing, vision changes, or redness of the eye, the patient should be instructed to immediately remove lenses and promptly contact his or her eyecare practitioner.

    CONTRAINDICATIONS:

    Do not use when any of the following conditions exist:

    • Acute or subacute inflammation or infection of the anterior chamber of the eye.
    • Any eye disease, injury or abnormality, other than keratoconus, PMD, that affects the cornea, conjunctiva or eyelids
    • Severe insufficiency of lacrimal secretion (dry eye)
    • Corneal hypoesthesia (reduced sensitivity), if not aphakic
    • Any systemic disease that may affect the eye or be exaggerated by wearing contact lenses
    • Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses or using contact lens solutions
    • Allergy to any ingredient in a solution which is to be used to care for contact lenses
    • Any active corneal infection (bacterial, fungal or viral)
    • Red or irritated eyes

    ADVERSE EFFECTS:

    The following problems may occur with the use of contact lenses:

    • Eyes stinging, burning, itching, irritation or other eye pain
    • Comfort is less than when the lens was first placed on the eye
    • Feeling of something in the eye such as a foreign body, scratched area
    • Excessive watering (tearing) of the eye
    • Unusual eye secretions
    • Redness of the eyes
    • Reduced sharpness of vision (poor visual acuity)
    • Blurred vision, rainbows, or halos around objects
    • Sensitivity to light (photophobia)
    • Dry eyes

    About HOAs

    HOAs are complex irregularities in the eye's lens or cornea that can significantly impact visual clarity. They result from factors such as irregularities in the corneal shape, scarring, previous eye surgeries, large pupils or certain medical conditions affecting the eye, such as keratoconus or other corneal dystrophies. They can also be induced by the aging process or from changes in the eye's internal structures. Patients who have HOAs can experience symptoms such as blurred vision, halos, glare and difficulty seeing in low light conditions such as driving at night.

    About Bausch + Lomb

    Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

    Reference

    1. Shah P, Gidosh N. Awesome vision after aberration control: the future of scleral lens optics. Poster presented at: The Global Specialty Lens Symposium; January 17-20, 2024; Las Vegas, NV.

    FocalPoints is a trademark of Advanced Medical.

    All other product/brand names are trademarks of the respective owners.

    © 2025 Bausch + Lomb.

    ALZN.0026.USA.25

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250514394244/en/

    Media:

    Kristy Marks

    [email protected]

    (908) 927-0683

    Get the next $BLCO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLCO

    DatePrice TargetRatingAnalyst
    12/11/2025$20.00Neutral → Buy
    Citigroup
    12/2/2025$21.00Equal-Weight → Overweight
    Morgan Stanley
    10/1/2025$16.00Neutral
    Goldman
    5/2/2025$20.00 → $15.00Buy
    H.C. Wainwright
    3/28/2025$24.00 → $15.00Overweight → Equal Weight
    Wells Fargo
    12/11/2024$24.00 → $22.00Buy → Neutral
    Citigroup
    12/2/2024$19.00Overweight → Equal-Weight
    Morgan Stanley
    10/15/2024$19.00 → $25.00In-line → Outperform
    Evercore ISI
    More analyst ratings

    $BLCO
    SEC Filings

    View All

    Bausch + Lomb Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Bausch & Lomb Corp (0001860742) (Filer)

    12/12/25 5:29:56 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Bausch & Lomb Corp (0001860742) (Filer)

    11/13/25 7:24:09 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    SEC Form 10-Q filed by Bausch + Lomb Corporation

    10-Q - Bausch & Lomb Corp (0001860742) (Filer)

    10/29/25 4:31:46 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bausch + Lomb Announces Refinancing of Outstanding Term B Loans

    Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "company"), a leading global eye health company dedicated to helping people see better to live better, today announced that it allocated a $2,802,125,000 tranche (the "Replacement Term Loans") of new term B loans, the proceeds of which will be used to refinance all of its outstanding term B loans due 2031 (the "Third Amendment Term Loans") and its outstanding term B loans due 2028 (the "First Incremental Term Loans"). The applicable margin is anticipated to be (i) 3.75% per annum for Replacement Term Loans with an interest rate determined by reference to term SOFR and (ii) 2.75% per annum for Replacement Term Loans with an in

    12/12/25 4:48:00 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb to Participate in Citi Global Healthcare Conference

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Executive Vice President and Chief Financial Officer Sam Eldessouky will participate in a fireside chat at the 2025 Citi Global Healthcare Conference on Wednesday, Dec. 3, 2025, at 9:00 a.m. ET. A live webcast, as well as a post-event recording, will be available on the Investor Relations page of the Bausch + Lomb website: http://ir.bausch.com/investors/events-presentations. About Bausch + Lomb Our mission is simple – we help people see better to live better, all over the world. For nearly two centu

    11/18/25 4:30:00 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    NYSE Content Advisory: Pre-Market Update + TKO and Polymarket Announce Partnership

    NEW YORK, Nov. 13, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Ashley Mastronardi delivers the pre-market update on November 13th Stocks are little changed Thursday morning after two major developments: A new partnership between NYSE-listed TKO Group Holdings and Polymarket, and the end of the longest U.S. Government shutdown.TKO Group Holdings and Polymarket will ring the opening bell with several guests including TKO Chair and CEO Ari Emanuel, Polymarket CEO Shayne Coplan, UFC CEO Dana White, and

    11/13/25 8:55:00 AM ET
    $BLCO
    $ICE
    $TKO
    Ophthalmic Goods
    Health Care
    Investment Bankers/Brokers/Service
    Finance

    $BLCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Robertson Russel C was granted 1,642 shares, increasing direct ownership by 3% to 66,556 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    11/18/25 4:42:57 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Director Paulson John was granted 1,402 shares, increasing direct ownership by 2% to 71,367 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    11/18/25 4:23:35 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    SVP, Controller and CAO Munsch Frederick was granted 7,529 shares, increasing direct ownership by 11% to 77,733 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    8/7/25 4:48:43 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman of the Board Saunders Brent L bought $248,072 worth of shares (22,000 units at $11.28) and was granted 22,000 shares, increasing direct ownership by 6% to 741,156 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    5/27/25 8:16:24 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Director Von Eschenbach Andrew C. bought $19,925 worth of shares (1,695 units at $11.76), increasing direct ownership by 4% to 41,748 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    5/6/25 4:30:10 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    CEO and Chairman of the Board Saunders Brent L bought $505,067 worth of shares (32,250 units at $15.66) and was granted 32,250 shares, increasing direct ownership by 11% to 627,419 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    8/7/24 5:29:48 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bausch + Lomb upgraded by Citigroup with a new price target

    Citigroup upgraded Bausch + Lomb from Neutral to Buy and set a new price target of $20.00

    12/11/25 8:44:49 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Bausch + Lomb from Equal-Weight to Overweight and set a new price target of $21.00

    12/2/25 8:17:09 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Goldman initiated coverage on Bausch + Lomb with a new price target

    Goldman initiated coverage of Bausch + Lomb with a rating of Neutral and set a new price target of $16.00

    10/1/25 8:44:08 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Leadership Updates

    Live Leadership Updates

    View All

    Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results

    Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the "Annual Meeting") held on May 21, 2025. Detailed results of the vote follow: Name For   Against   Broker Non-Votes Nathalie Bernier   337,617,248   1,924,336   8,383,437 Gary Hu   337,591,706   1,949,878   8,383,437 Brett Icahn   337,474,287   2,067,297   8,383,437 Sarah B. Kavanagh   337,602,211   1,939,373  

    5/21/25 4:30:00 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors

    Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling's appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting. "Since my return to the company, Richard has been a trusted advisor,

    2/28/24 8:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

    Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai

    2/21/24 7:00:00 AM ET
    $BLCO
    $EBS
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BLCO
    Financials

    Live finance-specific insights

    View All

    Bausch + Lomb Announces Third-Quarter 2025 Results

    Revenue of $1.281 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $28 Million Adjusted EBITDA (non-GAAP)1 of $243 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $243 Million Revenue Grew 7% as Reported and 6% on a Constant Currency1 Basis Compared to the Third Quarter of 2024 Updating Full-Year 2025 Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 Guidance Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2025 financial results. "We're delivering on the vision we laid out in 2023, with a base business engine that con

    10/29/25 6:58:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter financial results on Wednesday, Oct. 29, 2025. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Bausch + Lomb will hold an investor day on Thursday, Nov. 13, 2025, where the company will provide a business update and highlight its product pipeline which features potential game-changing innovations in each business unit. T

    9/29/25 7:15:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces Second-Quarter 2025 Results

    Revenue of $1.278 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $62 Million Adjusted EBITDA (non-GAAP)1 of $191 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $192 Million Revenue Grew 5% as Reported and 3% on a Constant Currency1 Basis Compared to the Second Quarter of 2024, which Absorbs the enVista® Intraocular Lenses Voluntary Recall Raising Full-Year 2025 Guidance to Reflect Solid Business Performance and Impact of Foreign Exchange Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2025 financial results. "Our con

    7/30/25 6:57:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bausch + Lomb Corporation

    SC 13G - Bausch & Lomb Corp (0001860742) (Subject)

    2/14/23 5:14:30 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care